Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Hold at Wall Street Zen

Trevi Therapeutics (NASDAQ:TRVI) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities analysts have also recently issued reports about the company. D. Boral Capital reissued a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a report on Friday, April 17th. Morgan Stanley reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. JonesTrading reduced their price target on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $22.90.

Trevi Therapeutics Price Performance

TRVI opened at $17.21 on Friday. The business’s fifty day simple moving average is $14.32 and its 200 day simple moving average is $12.62. Trevi Therapeutics has a 52 week low of $5.41 and a 52 week high of $17.61. The stock has a market cap of $2.44 billion, a PE ratio of -53.78 and a beta of 1.04.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, equities analysts anticipate that Trevi Therapeutics will post -0.47 earnings per share for the current year.

Institutional Trading of Trevi Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its stake in shares of Trevi Therapeutics by 20.4% in the first quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock worth $174,000 after buying an additional 4,688 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Trevi Therapeutics by 31.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock valued at $278,000 after buying an additional 10,445 shares during the last quarter. Millennium Management LLC boosted its position in Trevi Therapeutics by 356.3% during the 1st quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock valued at $5,178,000 after buying an additional 642,830 shares during the period. Strs Ohio purchased a new stake in Trevi Therapeutics during the 1st quarter valued at $52,000. Finally, Creative Planning boosted its position in Trevi Therapeutics by 17.5% during the 2nd quarter. Creative Planning now owns 20,247 shares of the company’s stock valued at $111,000 after buying an additional 3,016 shares during the period. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.